The outcome of COVID‐19 in patients with hematological malignancy

I have read with great interest the recently published paper by Yigenoglu et al. entitled, “The outcome of COVID‐19 in patients with hematological malignancy”.

Saved in:
Bibliographic Details
Published in:Journal of Medical Virology 2021-03, Vol.93 (3), p.1229-1229
Main Author: Cakir, Banu
Format: Article
Language:English
Subjects:
Actin Depolymerizing Factors
CD4-Positive T-Lymphocytes
Cell Movement
COVID-19
Hematologic Neoplasms - complications
Hematology
HIV Infections
Humans
Immune Reconstitution
Letter to the Editor
Letters to the Editor
Malignancy
SARS-CoV-2
Virology
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4716-1d9fc0a36688062a78a2bc280c38cf2b220535b1f943f29fe08ec1c2facd72cc3
cites
container_end_page 1229
container_issue 3
container_start_page 1229
container_title Journal of Medical Virology
container_volume 93
creator Cakir, Banu
description I have read with great interest the recently published paper by Yigenoglu et al. entitled, “The outcome of COVID‐19 in patients with hematological malignancy”.
doi_str_mv 10.1002/jmv.26576
format article
fullrecord <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7537540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2448404620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4716-1d9fc0a36688062a78a2bc280c38cf2b220535b1f943f29fe08ec1c2facd72cc3</originalsourceid><addsrcrecordid>eNp90ctKxDAUBuAgio6XhS8gBTe6qJ6kaS4bQcY7iht1GzKZZCZD24xNq8zOR_AZfRKro6KCrs7ifPycw4_QJoY9DED2J-XDHmE5Zwuoh0GyVALHi6gHmLKUMZyvoNUYJwAgJCHLaCXLABgF2UP9m7FNQtuYUHbTJf3ru_Ojl6dnLBNfJVPdeFs1MXn0zTgZ21I3oQgjb3SRlLrwo0pXZraOlpwuot34mGvo9uT4pn-WXl6fnvcPL1NDOWYpHkpnQGeMCQGMaC40GRgiwGTCODIgBPIsH2AnaeaIdBaENdgQp82QE2OyNXQwz522g9IOTXdZrQs1rX2p65kK2qufm8qP1Sg8KJ5nPKfQBex8BNThvrWxUaWPxhaFrmxooyKUCgqUkTe6_YtOQltX3XudEliC5AT_r6gAzti72p0rU4cYa-u-Tsag3gpUXYHqvcDObn3_8Ut-NtaB_Tl49IWd_Z2kLq7u5pGvD76kTA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448076621</pqid></control><display><type>article</type><title>The outcome of COVID‐19 in patients with hematological malignancy</title><source>Coronavirus Research Database</source><creator>Cakir, Banu</creator><creatorcontrib>Cakir, Banu</creatorcontrib><description>I have read with great interest the recently published paper by Yigenoglu et al. entitled, “The outcome of COVID‐19 in patients with hematological malignancy”.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.26576</identifier><identifier>PMID: 33006409</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Actin Depolymerizing Factors ; CD4-Positive T-Lymphocytes ; Cell Movement ; COVID-19 ; Hematologic Neoplasms - complications ; Hematology ; HIV Infections ; Humans ; Immune Reconstitution ; Letter to the Editor ; Letters to the Editor ; Malignancy ; SARS-CoV-2 ; Virology</subject><ispartof>Journal of Medical Virology, 2021-03, Vol.93 (3), p.1229-1229</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com</rights><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4716-1d9fc0a36688062a78a2bc280c38cf2b220535b1f943f29fe08ec1c2facd72cc3</citedby><orcidid>0000-0001-6645-6527</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2448076621?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,38516,43895</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2448076621?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33006409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cakir, Banu</creatorcontrib><title>The outcome of COVID‐19 in patients with hematological malignancy</title><title>Journal of Medical Virology</title><addtitle>J Med Virol</addtitle><description>I have read with great interest the recently published paper by Yigenoglu et al. entitled, “The outcome of COVID‐19 in patients with hematological malignancy”.</description><subject>Actin Depolymerizing Factors</subject><subject>CD4-Positive T-Lymphocytes</subject><subject>Cell Movement</subject><subject>COVID-19</subject><subject>Hematologic Neoplasms - complications</subject><subject>Hematology</subject><subject>HIV Infections</subject><subject>Humans</subject><subject>Immune Reconstitution</subject><subject>Letter to the Editor</subject><subject>Letters to the Editor</subject><subject>Malignancy</subject><subject>SARS-CoV-2</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNp90ctKxDAUBuAgio6XhS8gBTe6qJ6kaS4bQcY7iht1GzKZZCZD24xNq8zOR_AZfRKro6KCrs7ifPycw4_QJoY9DED2J-XDHmE5Zwuoh0GyVALHi6gHmLKUMZyvoNUYJwAgJCHLaCXLABgF2UP9m7FNQtuYUHbTJf3ru_Ojl6dnLBNfJVPdeFs1MXn0zTgZ21I3oQgjb3SRlLrwo0pXZraOlpwuot34mGvo9uT4pn-WXl6fnvcPL1NDOWYpHkpnQGeMCQGMaC40GRgiwGTCODIgBPIsH2AnaeaIdBaENdgQp82QE2OyNXQwz522g9IOTXdZrQs1rX2p65kK2qufm8qP1Sg8KJ5nPKfQBex8BNThvrWxUaWPxhaFrmxooyKUCgqUkTe6_YtOQltX3XudEliC5AT_r6gAzti72p0rU4cYa-u-Tsag3gpUXYHqvcDObn3_8Ut-NtaB_Tl49IWd_Z2kLq7u5pGvD76kTA</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Cakir, Banu</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>COVID</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6645-6527</orcidid></search><sort><creationdate>202103</creationdate><title>The outcome of COVID‐19 in patients with hematological malignancy</title><author>Cakir, Banu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4716-1d9fc0a36688062a78a2bc280c38cf2b220535b1f943f29fe08ec1c2facd72cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Actin Depolymerizing Factors</topic><topic>CD4-Positive T-Lymphocytes</topic><topic>Cell Movement</topic><topic>COVID-19</topic><topic>Hematologic Neoplasms - complications</topic><topic>Hematology</topic><topic>HIV Infections</topic><topic>Humans</topic><topic>Immune Reconstitution</topic><topic>Letter to the Editor</topic><topic>Letters to the Editor</topic><topic>Malignancy</topic><topic>SARS-CoV-2</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cakir, Banu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Coronavirus Research Database</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Medical Virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Cakir, Banu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The outcome of COVID‐19 in patients with hematological malignancy</atitle><jtitle>Journal of Medical Virology</jtitle><addtitle>J Med Virol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>93</volume><issue>3</issue><spage>1229</spage><epage>1229</epage><pages>1229-1229</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>I have read with great interest the recently published paper by Yigenoglu et al. entitled, “The outcome of COVID‐19 in patients with hematological malignancy”.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33006409</pmid><doi>10.1002/jmv.26576</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6645-6527</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0146-6615
ispartof Journal of Medical Virology, 2021-03, Vol.93 (3), p.1229-1229
issn 0146-6615
1096-9071
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7537540
source Coronavirus Research Database
subjects Actin Depolymerizing Factors
CD4-Positive T-Lymphocytes
Cell Movement
COVID-19
Hematologic Neoplasms - complications
Hematology
HIV Infections
Humans
Immune Reconstitution
Letter to the Editor
Letters to the Editor
Malignancy
SARS-CoV-2
Virology
title The outcome of COVID‐19 in patients with hematological malignancy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A29%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20outcome%20of%20COVID%E2%80%9019%20in%20patients%20with%20hematological%20malignancy&rft.jtitle=Journal%20of%20Medical%20Virology&rft.au=Cakir,%20Banu&rft.date=2021-03&rft.volume=93&rft.issue=3&rft.spage=1229&rft.epage=1229&rft.pages=1229-1229&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.26576&rft_dat=%3Cproquest_COVID%3E2448404620%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4716-1d9fc0a36688062a78a2bc280c38cf2b220535b1f943f29fe08ec1c2facd72cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2448076621&rft_id=info:pmid/33006409&rfr_iscdi=true